LIGAND PHARMACEUTICALS AND TAP PHARMACEUTICAL PRODUCTS SIGN COLLABORATIVE RESEARCH AGREEMENT

TAP Pharmaceutical Products Inc. and Ligand Pharmaceuticals Incorporated, announced today the initiation of a joint research and development alliance that will focus on the discovery and development of selective androgen receptor modulators (SARMs). SARMs may contribute to the prevention and treatment of certain diseases, including hypogonadism (low-testosterone), male and female sexual dysfunction, male and female osteoporosis, frailty, and male hormone replacement therapy (HRT).

Click here for more information on Ligand Pharmaceuticals Inc. and to access Ligand's press release regarding this announcement.